Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Trump Admin Releases Final Rule Attacking Healthcare for Low-Income Trans Kids

Since President Donald Trump returned to the White House, he’s been vowing to stamp out gender-affirming medical care—what his administration terms “sex-rejecting procedures”—for young people diagnosed with gender dysphoria. Now, his administration is specifically going after the health care of trans kids from low-income families. On Tuesday, the Centers for Medicare & Medicaid Services released…

President Donald Trump's administration has released a final rule that attacks healthcare for low-income transgender children. The Centers for Medicare & Medicaid Services announced the rule on Tuesday, which denies Medicaid and the Children’s Health Insurance Program from paying for puberty blockers, hormone therapy, and surgeries to treat gender dysphoria in young patients.

The rule affects patients under 18 for Medicaid and under 19 for CHIP and will take effect in October, with an exception for patients already on cross-sex hormones. This rule, which the administration claims is based on scientific consensus, is supported by a report commissioned by the Trump administration and authored by conservative activists.

Critics of the rule, including the American Academy of Pediatrics, argue that it misrepresents the medical consensus and fails to reflect the realities of pediatric care. The rule is part of a broader effort by the Trump administration to limit access to gender-affirming care for minors, with nearly 35,000 public comments received opposing the new regulation.

Written by urgent.news from Mother Jones's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at motherjones.com →

More in Health & Medicine

Celltrion Expands Market Presence in Spain and Portugal Through Tender Wins

Celltrion is rapidly strengthening its presence in Spain and Portugal, securing a series of government and regional tenders while expanding sales and marketing activities to drive prescriptions and…

  • Celltrion wins government tenders in Spain and Portugal, expanding market presence.
  • Omlyclo biosimilar dominates Spanish market with 90% share by June.
  • Actemra and other biosimilars gain significant market share in Spain and Portugal.

JW Pharmaceutical’s Gout Drug Candidate Outperforms Febuxostat in Phase 3 Trial

JW Pharmaceutical has reported positive results from a multinational Phase 3 trial of its gout drug candidate epaminurad (code name URC102), with the 6mg dose demonstrating statistically superior…

  • JW Pharmaceutical's epaminurad (URC102) outperformed febuxostat in Phase 3 gout trial.
  • Epaminurad achieved 50.0% serum uric acid reduction vs. 38.3% for febuxostat 40mg.
  • Safety profiles were comparable with no drug-related deaths reported.

More from Wednesday 12 August →